Litcius/Paper detail

Differences in plasma metabolites related to Alzheimer's disease, <i>APOE</i> ε4 status, and ethnicity

Badri N. Vardarajan, Vrinda Kalia, Jennifer J. Manly, Adam M. Brickman, Dolly Reyes‐Dumeyer, Rafael Lantigua, Iuliana Ionita‐Laza, Dean P. Jones, Gary W. Miller, Richard Mayeux

2020Alzheimer s & Dementia Translational Research & Clinical Interventions25 citationsDOIOpen Access PDF

Abstract

Abstract Introduction We investigated metabolites in plasma to capture systemic biochemical changes associated with Alzheimer's disease (AD). Methods Metabolites in plasma were measured in 59 AD cases and 60 healthy participants of African American (AA), Caribbean Hispanic (CH), and non‐Hispanic white (NHW) ancestry using untargeted liquid‐chromatography–based ultra‐high‐resolution mass spectrometry. Metabolite differences between AD and healthy, ethnic groups and apolipoprotein E gene ( APOE ) ε4 status were analyzed. Untargeted network analysis identified pathways enriched in AD‐associated metabolites. Results A total of 5929 annotated metabolites were measured. Partial least squares discriminant analysis (PLS‐DA) inferred that AD clustered separately from healthy controls (area under the curve [AUC] = 0.9816); discriminating pathways included glycerophospholipid, sphingolipid, and non‐essential amino acid (alanine, aspartate, glutamate) metabolism. Metabolic features in AA clustered differently from CH and NHW (AUC = 0.9275), and differed between APOE ε4 carriers and non‐carriers (AUC = 0.9972). Discussion Metabolites, specifically lipids, were associated with AD, APOE ε4, and ethnic group. Metabolite profiling can identify perturbed AD pathways, but genetic and ancestral background need to be considered.

Topics & Concepts

MetaboliteApolipoprotein ESphingolipidChemistryBiologyDiseaseInternal medicineBiochemistryMedicineMetabolomics and Mass Spectrometry StudiesAlzheimer's disease research and treatmentsMitochondrial Function and Pathology